Let’s work together to build a future where dementia is a thing of the past.

We offer groundbreaking digital diagnostic and monitoring tools that enable early detection of memory decline years before the onset of symptoms. Early intervention is key to improved treatment outcomes and enhanced quality of life.



Rapid, reliable, and objective assessments of memory decline.​

Augmem uses neural circuit-based approaches backed by proprietary AI to create highly sensitive digital diagnostic and monitoring tools.

Tests are backed by over 15 years of academic research and more than 50 peer-reviewed publications.


Why Does Augmem Matter to Clinical Trials & Research?

Augmem provides precise and accurate tracking of memory performance. Our pathbreaking technology is a world leader in screening, stratification, diagnosis, monitoring, and evaluation of treatment response.


Why Does Augmem Matter to Healthcare Professionals?

Augmem detects subtle shifts in cognition, before the onset of symptoms. Our precision tools enable earlier diagnosis and intervention, leading to better prognoses, lower treatment costs and prolonged quality of life for patients. ​


Scientific Team

Michael A. Yassa, Ph.D.


Dr. Yassa is recognized for his highly cited work on memory alterations in aging and Alzheimer’s disease. His laboratory develops innovative high-resolution human imaging techniques and digital cognitive tests to probe brain circuits at fine levels of detail. Over the last 20 years, his work has focused on digital and neural biomarker development for age-related cognitive decline and dementia.

To date, Dr. Yassa’s work has yielded over 100 peer-reviewed publications and over $50M in federal grant funding. He is professor and James L. McGaugh Endowed Chair with appointments in Neurobiology, Neurology, Psychiatry, and Psychology at the University of California, Irvine, and director of the world-renowned Center for the Neurobiology of Learning and Memory, founded in 1983. Dr. Yassa earned his BA in Neuroscience and MA in Psychology from the Johns Hopkins University and a PhD in Neurobiology from the University of California, Irvine.

Adele Gilpin, Ph.D., J.D.


Dr. Gilpin works at the interface of clinical trials design and conduct, and FDA regulatory requirements. As a clinical trials methodologist and a Food and Drug Regulatory attorney, she primarily works on bringing new neurological medical devices to market, with particular attention to the FDA hurdles in investigational products, and complying with FDA requirements. Her work has included designing and conducting multicenter drug and device clinical trials, and chairing or participating in multiple Institutional Review Boards and Data and Safety Monitoring Boards.

Dr. Gilpin brings decades of experience both in academic medical research – at the Johns Hopkins School of Public Health and the University of Maryland School of Medicine – and in FDA legal/regulatory practice – at AMLAW 100 law firm bioscience practices. Dr. Gilpin is a visiting faculty member at the Center for the Neurobiology of Learning, Memory and Behavior at the University of California Irvine. She has a BA in Psychology, an MA and PhD in Quantitative Psychology from Temple University, and a JD from Georgetown University Law Center.

Marco Peters, Ph.D.


Dr. Peters has over 20 years of experience in translational research, target discovery, and small molecule discovery for CNS indications. Dr. Peters built and managed small and large research teams, and his work has contributed to the discovery, progression, and clinical development of small molecule therapeutics for the treatment of multiple neurological indications including stroke, Alzheimer’s Disease, Parkinson’s disease, Pain, and Schizophrenia. He currently serves as Vice President, Head of Translational Science at Longboard Pharmaceuticals. Prior to joining Longboard, Dr. Peters held positions of increasing responsibility at Dart Neuroscience, where he built the departments of Neurobiology and Behavioral Pharmacology, and managed target ID, in vivo pharmacology, and lead optimization. His work at Dart contributed to the advancement of multiple compounds into clinical development, and a broad intellectual property portfolio focused on enhancement of brain plasticity and cognitive function. Dr. Peters holds a Ph.D. in Neuroscience from the University of London, UK, and an M.Sc. in Biochemistry with distinction from the Freie Universität Berlin, Germany. He conducted post-doctoral work on Alzheimer’s disease with Tetsuyuki Maruyama at Merck Sharp & Dohme (UK).

Andrew Anderson, B.Sc., M.B.A.

Principal Technical Advisor

Andrew serves as Principal Technical Advisor for Augnition—managing an ecosystem of technology partners to develop and commercialize platform applications.  His focus is to deliver applications that meet the scientific, technical, and user-experience expectations of end-users, influencers, and beneficiaries.

Andrew started his career as an analytical chemist and regulatory CMC specialist at Pfizer before moving into various business development and strategic partnership roles at scientific software and automation services organizations. More recently, Andrew was responsible for technology scouting and alliance management at PepsiCo.  In addition to his role with Augnition, Andrew is also a part of the Executive Leadership Team at Advanced Chemistry Development, Inc., serving as Vice President of Innovation.  Andrew earned a B.Sc. in Chemistry and an MBA from San Diego State University.


Overall Approach

Yassa, M.A., Stark, C.E. (2011) Pattern separation in the hippocampus. Trends in Neuroscience, 34(10), 515-25.

Leal, S. L., & Yassa, M. A. (2018). Integrating new findings and examining clinical applications of pattern separation. Nature Neuroscience, 21(2), 163–173.

Key Augmem Citations

Object task:
 Stark, S. M., Yassa, M. A., Lacy, J. W., & Stark, C. E. (2013). A task to assess behavioral pattern separation (BPS) in humans: Data from healthy aging and mild cognitive impairment. Neuropsychologia, 51(12), 2442–2449.

Spatial task:
 Reagh, Z. M., Roberts, J. M., Ly, M., DiProspero, N., Murray, E., & Yassa, M. A. (2014). Spatial discrimination deficits as a function of mnemonic interference in aged adults with and without memory impairment. Hippocampus, 24(3), 303–314.

Temporal task:
 Roberts, J. M., Ly, M., Murray, E., & Yassa, M. A. (2014). Temporal discrimination deficits as a function of lag interference in older adults. Hippocampus, 24(10), 1189–1196.

Use in acute interventions

Caffeine: Borota, D., Murray, E., Keceli, G., Chang, A., Watabe, J.M., Ly, M., Toscano, J.P., Yassa, M.A. (2014) Post-study caffeine administration enhances memory consolidation in humans. Nature Neuroscience, 17(2):201-3.

Exercise: Suwabe, K., Byun, K., Hyodo, K., Reagh, Z. M., Roberts, J. M., Matsushita, A., Saotome, K., Ochi, G., Fukuie, T., Suzuki, K., Sankai, Y., Yassa, M. A., & Soya, H. (2018). Rapid stimulation of human dentate gyrus function with acute mild exercise. Proceedings of the National Academy of Sciences of the United States of America, 115(41), 10487–10492.

Use in Phase 2 and 3 Clinical Trials

Bakker, A., Krauss, G. L., Albert, M. S., Speck, C. L., Jones, L. R., Stark, C. E., Yassa, M. A., Bassett, S. S., Shelton, A. L., & Gallagher, M. (2012). Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron, 74(3), 467–474.

Papp, K. V., Rentz, D. M., Maruff, P., Sun, C. K., Raman, R., Donohue, M. C., Schembri, A., Stark, C., Yassa, M. A., Wessels, A. M., Yaari, R., Holdridge, K. C., Aisen, P. S., & Sperling, R. A. (2021). The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. The Journal of Prevention of Alzheimer's Disease, 8(1), 59–67.


For inquiries, please contact info@augnitionlabs.com